

Elisa Gremese

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3471866/elisa-gremese-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198
papers

4,075
citations

35
h-index

55
g-index

222
ext. papers

5,369
ext. citations

5.7
avg, IF

5.39
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 198 | Immune-guided therapy of COVID-19.. <i>Cancer Immunology Research</i> , 2022 , | 12.5 | 2 |
| 197 | Pro Nerve Growth Factor and Its Receptor p75NTR Activate Inflammatory Responses in Synovial Fibroblasts: A Novel Targetable Mechanism in Arthritis.. <i>Frontiers in Immunology</i> , 2022 , 13, 818630 | 8.4 | 0 |
| 196 | Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis (RA) reconsidered.. <i>Autoimmunity Reviews</i> , 2022 , 103102 | 13.6 | 0 |
| 195 | Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 681327 | 5.4 | 0 |
| 194 | Loss of α -6 sialylation promotes the transformation of synovial fibroblasts into a pro-inflammatory phenotype in arthritis. <i>Nature Communications</i> , 2021 , 12, 2343 | 17.4 | 4 |
| 193 | Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021 , 40, 4039-4047 | 3.9 | 0 |
| 192 | Simultaneous Onset of Mycobacterium kansasii Pulmonary Infection and Systemic Lupus Erythematosus: A Case Report. <i>American Journal of Case Reports</i> , 2021 , 22, e929866 | 1.3 | |
| 191 | RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118, | 11.5 | 0 |
| 190 | Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1419-1428 | 2.4 | 0 |
| 189 | COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. <i>JCI Insight</i> , 2021 , 6, | 9.9 | 8 |
| 188 | Comprehensive review on intravertebral intraspinal, intrajoint, and intradiscal vacuum phenomenon: From anatomy and physiology to pathology. <i>Modern Rheumatology</i> , 2021 , 31, 303-311 | 3.3 | 4 |
| 187 | Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021 , 60, 728-736 | 3.9 | 4 |
| 186 | Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021 , 88, 105062 | 2.9 | 5 |
| 185 | Psoriatic arthritis and depressive symptoms: does systemic inflammation play a role?. <i>Clinical Rheumatology</i> , 2021 , 40, 1893-1902 | 3.9 | 1 |
| 184 | Predictive Factors for a New Positive Nasopharyngeal Swab Among Patients Recovered From COVID-19. <i>American Journal of Preventive Medicine</i> , 2021 , 60, 13-19 | 6.1 | 19 |
| 183 | Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021 , 133, 104071 | 3.7 | 21 |
| 182 | Predicting In-Hospital Mortality in COVID-19 Older Patients with Specifically Developed Scores. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 37-43 | 5.6 | 32 |

| | | | |
|-----|--|------|----|
| 181 | Basophil activation and serum IL-5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti-IL-5 drugs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 1569-1571 | 9.3 | 2 |
| 180 | Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 97-104 | 5.4 | 1 |
| 179 | The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab015 | 1.1 | 0 |
| 178 | The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target. <i>Journal of Internal Medicine</i> , 2021 , 289, 420-421 | 10.8 | 7 |
| 177 | Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study. <i>Frontiers in Medicine</i> , 2021 , 8, 613889 | 4.9 | 0 |
| 176 | Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks. <i>Annals of the Rheumatic Diseases</i> , 2021 , | 2.4 | 2 |
| 175 | Inclusion of Synovial Tissue-Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1601-1613 | 9.5 | 2 |
| 174 | () as a Potential Driver of Molecular Mimicry and Inflammation in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2021 , 8, 671018 | 4.9 | 2 |
| 173 | Compassionate use of anti-IL6 receptor antibodies in critically ill patients with acute respiratory distress syndrome due to SARS-CoV-2. <i>Minerva Anestesiologica</i> , 2021 , 87, 1080-1090 | 1.9 | 2 |
| 172 | Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship?. <i>Frontiers in Medicine</i> , 2021 , 8, 669397 | 4.9 | |
| 171 | Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14755 | 2.9 | 5 |
| 170 | Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021 , 124, 102729 | 15.5 | 3 |
| 169 | Reply to: Individuality of the composition of the human microbiota by Fernández-Estupiñ et al. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 128, 34 | 2.2 | |
| 168 | An unusual lung involvement in scleroderma: lipid pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 131, 161-162 | 2.2 | |
| 167 | An unusual lung involvement in scleroderma: lipid pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 161-162 | 2.2 | 0 |
| 166 | Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study. <i>Journal of Translational Autoimmunity</i> , 2020 , 3, 100072 | 4.1 | 0 |
| 165 | One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 813-821 | 5.4 | 18 |
| 164 | Post-COVID-19 global health strategies: the need for an interdisciplinary approach. <i>Aging Clinical and Experimental Research</i> , 2020 , 32, 1613-1620 | 4.8 | 78 |

| | | | |
|-----|---|------|-----|
| 163 | Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 1782-1783 | 3.9 | 1 |
| 162 | Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020 , 7, 42 | 4.9 | 6 |
| 161 | Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. <i>Nature Medicine</i> , 2020 , 26, 1295-1306 | 50.5 | 115 |
| 160 | Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. <i>Infection</i> , 2020 , 48, 767-771 | 5.8 | 21 |
| 159 | Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13342 | 4.6 | 8 |
| 158 | Morbidity and Mortality From COVID-19 Are Not Increased Among Children or Patients With Autoimmune Rheumatic Disease-Possible Immunologic Rationale: Comment on the Article by Henderson et al. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1772-1774 | 9.5 | 1 |
| 157 | Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. <i>Journal of Autoimmunity</i> , 2020 , 108, 102397 | 15.5 | 10 |
| 156 | Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. <i>Clinical Immunology</i> , 2020 , 214, 108395 | 9 | 9 |
| 155 | Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1314-1324 | 9.5 | 24 |
| 154 | Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 681-692 | 2.3 | 1 |
| 153 | Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. <i>Rheumatology</i> , 2020 , 59, 2523-2533 | 3.9 | 13 |
| 152 | Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. <i>Annals of Laboratory Medicine</i> , 2020 , 40, 101-113 | 3.1 | 10 |
| 151 | Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , 2020 , 50, 1085-1090 | 1.6 | 38 |
| 150 | No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic. <i>Rheumatology</i> , 2020 , 59, 2644-2646 | 3.9 | |
| 149 | Adult Onset Still's Disease and Radiotherapy treatment for breast cancer: Case report about management of this rare association and literature review. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020 , 25, 527-532 | 1.5 | 2 |
| 148 | What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102666 | 13.6 | 10 |
| 147 | Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 902-903 | 6.1 | 5 |
| 146 | Sarilumab use in severe SARS-CoV-2 pneumonia. <i>EClinicalMedicine</i> , 2020 , 27, 100553 | 11.3 | 47 |

| | | | |
|-----|--|------|-----|
| 145 | Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , 2020 , 59, 3731-3736 | 3.9 | 10 |
| 144 | Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020 , 27, 2322-2328 | 6 | 19 |
| 143 | Correspondence on Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis <i>Annals of the Rheumatic Diseases</i> , 2020 , | 2.4 | 6 |
| 142 | COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020 , 52, 1231-1233 | 3.3 | 20 |
| 141 | Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. <i>Frontiers in Medicine</i> , 2020 , 7, 553075 | 4.9 | 2 |
| 140 | Correspondence to Gender gap in rheumatology: speaker representation at annual conferences by Monga and Liew-gender discrepancies at annual EULAR congresses: towards the gap narrowing. <i>Annals of the Rheumatic Diseases</i> , 2020 , | 2.4 | 1 |
| 139 | Pulmonary intravascular coagulopathy in COVID-19 pneumonia. <i>Lancet Rheumatology</i> , 2020 , 2, e458 | 4.2 | 6 |
| 138 | Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 963-974 | 35.1 | 112 |
| 137 | Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry by Gianfrancesco M . The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020 , | 2.4 | 1 |
| 136 | Positive RT-PCR nasopharyngeal swab in patients recovered from COVID-19 disease: When does quarantine really end?. <i>Journal of Infection</i> , 2020 , 81, e1-e3 | 18.9 | 23 |
| 135 | Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement. <i>Diagnostics</i> , 2020 , 10, | 3.8 | 3 |
| 134 | Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020 , 35, 163-169 | 0.9 | 0 |
| 133 | Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. <i>Annals of the Rheumatic Diseases</i> , 2020 , | 2.4 | 5 |
| 132 | Telemedicine will not keep us apart in COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2020 , | 2.4 | 18 |
| 131 | Comparative analysis of synovial inflammation after SARS-CoV-2 infection. <i>Annals of the Rheumatic Diseases</i> , 2020 , | 2.4 | 19 |
| 130 | Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of Italy. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 88-93 | 2.2 | 4 |
| 129 | Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 125, 73-84 | 2.2 | 3 |
| 128 | The B side of rheumatoid arthritis pathogenesis. <i>Pharmacological Research</i> , 2019 , 149, 104465 | 10.2 | 7 |

| | | | |
|-----|--|------|----|
| 127 | PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. <i>Therapeutic Advances in Chronic Disease</i> , 2019 , 10, 2040622319847056 | 4.9 | 3 |
| 126 | Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 116 | 5.7 | 12 |
| 125 | Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. <i>European Journal of Internal Medicine</i> , 2019 , 66, 57-61 | 3.9 | 7 |
| 124 | Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. <i>Digestive and Liver Disease</i> , 2019 , 51, 972-977 | 3.3 | 13 |
| 123 | Long-Term Retention Rate of Anakinra in Adult Onset Still Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019 , 10, 296 | 5.6 | 17 |
| 122 | Comment on: Emergence of severe spondyloarthritis-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , 2019 , 58, 1113-1115 | 3.9 | 6 |
| 121 | Quantitative and semi-quantitative computed tomography analysis of interstitial lung disease associated with systemic sclerosis: A longitudinal evaluation of pulmonary parenchyma and vessels. <i>PLoS ONE</i> , 2019 , 14, e0213444 | 3.7 | 9 |
| 120 | Selective Inhibitors of T Cell Receptor Recognition of Antigen-MHC Complexes for Rheumatoid Arthritis. <i>ACS Medicinal Chemistry Letters</i> , 2019 , 10, 644-649 | 4.3 | 4 |
| 119 | Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. <i>Autoimmunity Reviews</i> , 2019 , 18, 565-575 | 13.6 | 34 |
| 118 | Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. <i>Autoimmunity Reviews</i> , 2019 , 18, 317-324 | 13.6 | 5 |
| 117 | Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers. <i>European Journal of Immunology</i> , 2019 , 49, 2195-2203 | 6.1 | 0 |
| 116 | JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. <i>Journal of Leukocyte Biology</i> , 2019 , 106, 1063-1068 | 6.5 | 27 |
| 115 | Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis. <i>Scientific Reports</i> , 2019 , 9, 10420 | 4.9 | 8 |
| 114 | Adult onset Still disease and pregnancy. <i>Autoimmunity Reviews</i> , 2019 , 18, 102356 | 13.6 | 3 |
| 113 | Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019 , 7, 1189-1197 | 5.3 | 18 |
| 112 | Diagnostic performance of FDG PET in large vessel vasculitis. <i>Clinical and Translational Imaging</i> , 2019 , 7, 415-425 | 2 | 1 |
| 111 | Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019 , 71, 599-611 | 9.5 | 96 |
| 110 | Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. <i>European Journal of Internal Medicine</i> , 2019 , 60, 46-53 | 3.9 | 29 |

| | | | |
|-----|--|------|----|
| 109 | Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. <i>Endocrine</i> , 2019 , 63, 369-375 | 4 | 15 |
| 108 | Incidence du cancer chez les patients atteints de spondyloarthrite traitée par anti-TNF. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019 , 86, 75-80 | 0.1 | |
| 107 | Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 649-655 | 2.2 | 9 |
| 106 | Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 1084-1091 | 2.2 | 2 |
| 105 | Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. <i>Journal of Clinical Pathology</i> , 2018 , 71, 620-625 | 3.9 | 11 |
| 104 | Should rheumatoid factor (RF) (and antinuclear antibodies (ANA)) become routinary screening test for morbidities in the general population?: From the concept of "benign autoimmunity "to the concept of" autoimmunity as a red flag in preventive medicine"?. <i>Autoimmunity Reviews</i> , 2018 , 17, 636-638 | 13.6 | 2 |
| 103 | Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. <i>Clinical and Experimental Immunology</i> , 2018 , 193, 13-23 | 6.2 | 21 |
| 102 | Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. <i>Arthritis Research and Therapy</i> , 2018 , 20, 75 | 5.7 | 24 |
| 101 | Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 351-359 | 1.9 | 6 |
| 100 | The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 619-629 | 5.3 | 9 |
| 99 | Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics register GISEA. <i>Clinical Rheumatology</i> , 2018 , 37, 315-321 | 3.9 | 27 |
| 98 | Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018 , 85, 455-459 | 2.9 | 11 |
| 97 | Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study. <i>Mediators of Inflammation</i> , 2018 , 2018, 6548715 | 4.3 | 19 |
| 96 | Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features. <i>Frontiers in Medicine</i> , 2018 , 5, 186 | 4.9 | 17 |
| 95 | Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders. <i>Immunotherapy</i> , 2018 , 10, 807-821 | 3.8 | 8 |
| 94 | Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018 , 5, 207 | 4.9 | 19 |
| 93 | Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1079-1088 | 1.5 | 41 |
| 92 | The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , 2018 , 57, vii11-vii22 | 3.9 | 11 |

| | | | |
|----|---|------|-----|
| 91 | Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. <i>Frontiers in Immunology</i> , 2018 , 9, 1936 | 8.4 | 51 |
| 90 | Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018 , 57, vii42-vii53 | 3.9 | 18 |
| 89 | The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018 , 17, 1251-1258 | 13.6 | 1 |
| 88 | Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018 , 4, e000667 | 5.9 | 11 |
| 87 | Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1228-1236 | 2.4 | 37 |
| 86 | Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra. <i>Medicine (United States)</i> , 2017 , 96, e6656 | 1.8 | 35 |
| 85 | MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. <i>Nature Communications</i> , 2017 , 8, 15877 | 17.4 | 51 |
| 84 | Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study. <i>Journal of Rheumatology</i> , 2017 , 44, 241-247 | 4.1 | 7 |
| 83 | MicroRNA-155-at the Critical Interface of Innate and Adaptive Immunity in Arthritis. <i>Frontiers in Immunology</i> , 2017 , 8, 1932 | 8.4 | 105 |
| 82 | B cell activating factor (BAFF) and BAFF receptors: fakes and facts. <i>Clinical and Experimental Immunology</i> , 2017 , 190, 291-292 | 6.2 | 16 |
| 81 | Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. <i>Autoimmunity Reviews</i> , 2017 , 16, 1096-1102 | 13.6 | 14 |
| 80 | Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. <i>Clinical Rheumatology</i> , 2017 , 36, 2151-2158 | 3.9 | 46 |
| 79 | An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. <i>Lupus</i> , 2017 , 26, 768-772 | 2.6 | 24 |
| 78 | Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017 , 8, 369 | 5.6 | 68 |
| 77 | The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2017 , 2017, 5230374 | 4.3 | 9 |
| 76 | Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 772-776 | 2.2 | 3 |
| 75 | Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 660-665 | 2.2 | 5 |
| 74 | Comment on "Tumor necrosis factor-antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study". <i>Clinical Rheumatology</i> , 2016 , 35, 839-40 | 3.9 | 1 |

| | | | |
|----|---|------|----|
| 73 | Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016 , 35, 2649-2656 ¹⁴ | 3.9 | 14 |
| 72 | MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. <i>Nature Communications</i> , 2016 , 7, 12970 | 17.4 | 72 |
| 71 | Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. <i>RMD Open</i> , 2016 , 2, e000263 | 5.9 | 3 |
| 70 | The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. <i>Clinical and Experimental Immunology</i> , 2016 , 184, 62-72 | 6.2 | 12 |
| 69 | Tapering and discontinuation of TNF-blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. <i>Arthritis Research and Therapy</i> , 2016 , 18, 39 | 5.7 | 46 |
| 68 | Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 751-62 | 5.1 | 9 |
| 67 | Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone. <i>Journal of the American Geriatrics Society</i> , 2016 , 64, 672-374 | 5.6 | 4 |
| 66 | Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al. <i>Arthritis and Rheumatology</i> , 2016 , 68, 553 | 9.5 | |
| 65 | Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2052-3 | 9.5 | 2 |
| 64 | Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016 , 3, e000163 | 4.6 | 34 |
| 63 | The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). <i>Medicine (United States)</i> , 2016 , 95, e5506 | 1.8 | 11 |
| 62 | CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 315-7 | 2.2 | 4 |
| 61 | Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement. <i>Journal of rheumatology Supplement, The</i> , 2015 , 93, 65-9 | | 5 |
| 60 | Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis. <i>EBioMedicine</i> , 2015 , 2, 2037-45 | 8.8 | 26 |
| 59 | The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015 , 54, 1074-1079 | 3.9 | 19 |
| 58 | Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography. <i>Clinical Rheumatology</i> , 2015 , 34, 1181-6 | 3.9 | 12 |
| 57 | Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. <i>Rheumatology</i> , 2015 , 54, 891-8 | 3.9 | 93 |
| 56 | Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 1-4 | 2.2 | 21 |

| | | | |
|----|--|------|-----|
| 55 | Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 449-56 | 2.2 | 51 |
| 54 | Body weight, gender and response to TNF- β blockers in axial spondyloarthritis. <i>Rheumatology</i> , 2014 , 53, 875-81 | 3.9 | 83 |
| 53 | Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. <i>Journal of Rheumatology</i> , 2014 , 41, 286-92 | 4.1 | 41 |
| 52 | Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. <i>Joint Bone Spine</i> , 2014 , 81, 508-12 | 2.9 | 15 |
| 51 | Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e31 | 2.4 | 7 |
| 50 | Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014 , 53, 2209-13 | 3.9 | 55 |
| 49 | Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis. <i>BMC Immunology</i> , 2014 , 15, 28 | 3.7 | 19 |
| 48 | Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). <i>Frontiers in Immunology</i> , 2014 , 5, 576 | 8.4 | 82 |
| 47 | High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. <i>Clinical Rheumatology</i> , 2014 , 33, 31-7 | 3.9 | 10 |
| 46 | The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, 869-77 | 2.2 | 39 |
| 45 | Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. <i>Arthritis Research and Therapy</i> , 2013 , 15, R66 | 5.7 | 43 |
| 44 | Obesity and reduction of the response rate to anti-tumor necrosis factor β in rheumatoid arthritis: an approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013 , 65, 94-100 | 4.7 | 137 |
| 43 | Tofacitinib for rheumatoid arthritis. <i>Lancet, The</i> , 2013 , 381, 1812 | 4.0 | 4 |
| 42 | Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. <i>Rheumatology</i> , 2013 , 52, 622 | 3.9 | 21 |
| 41 | Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 858-62 | 2.4 | 91 |
| 40 | Should we consider tumor necrosis factor as the only target in spondyloarthritis?. <i>Journal of rheumatology Supplement, The</i> , 2012 , 89, 94-6 | | 2 |
| 39 | Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012 , 12, 225-9 | 13.6 | 125 |
| 38 | Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. <i>PLoS ONE</i> , 2012 , 7, e40362 | 3.7 | 28 |

| | | | |
|----|--|------|-----|
| 37 | Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. <i>Reumatismo</i> , 2012 , 64, 368-73 | 1.1 | 4 |
| 36 | Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1309-15 | 2.4 | 19 |
| 35 | ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2012 , 39, 2276-85 | 4.1 | 5 |
| 34 | Longterm retention of tumor necrosis factor- β inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. <i>Journal of Rheumatology</i> , 2012 , 39, 1179-84 | 4.1 | 80 |
| 33 | Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. <i>Rheumatology</i> , 2012 , 51, 157-68 | 3.9 | 72 |
| 32 | Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia 2012 , 185-190 | | |
| 31 | Rheumatoid arthritis and Alzheimer [®] disease: genetic and epigenetic links in inflammatory regulation. <i>Discovery Medicine</i> , 2012 , 14, 379-88 | 2.5 | 18 |
| 30 | PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis. <i>PLoS ONE</i> , 2011 , 6, e24292 | 3.7 | 38 |
| 29 | B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status. <i>Molecular Medicine</i> , 2011 , 17, 901-9 | 6.2 | 24 |
| 28 | Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections. <i>Reumatismo</i> , 2011 , 63, 5-10 | 1.1 | 8 |
| 27 | The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. <i>Autoimmunity Reviews</i> , 2011 , 10, 582-9 | 13.6 | 71 |
| 26 | Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. <i>Clinical Immunology</i> , 2011 , 138, 107-16 | 9 | 45 |
| 25 | Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). <i>Internal and Emergency Medicine</i> , 2011 , 6 Suppl 1, 11-5 | 3.7 | 13 |
| 24 | Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 172-5 | 2.4 | 135 |
| 23 | Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1292-5 | 2.4 | 56 |
| 22 | Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2011 , 141, w13211 | 3.1 | 17 |
| 21 | Interleukin-1 β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. <i>Molecular Medicine</i> , 2010 , 16, 552-7 | 6.2 | 75 |
| 20 | Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 829-34 | 5.9 | 15 |

| | | | |
|----|--|------|----|
| 19 | Residual minimal disease activity in rheumatoid arthritis: a simple definition through an in-depth statistical analysis of the major outcome. <i>Rheumatology</i> , 2009 , 48, 1242-6 | 3.9 | 6 |
| 18 | Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 416-9 | 2.4 | 22 |
| 17 | Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. <i>Clinical Immunology</i> , 2009 , 131, 98-108 | 9 | 11 |
| 16 | ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. <i>Arthritis Research and Therapy</i> , 2009 , 11, R163 | 5.7 | 22 |
| 15 | Chapter 8 Gastrointestinal Involvement in Systemic Vasculitis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008 , 8, 83-298 | 0.3 | |
| 14 | B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids. <i>Acta Diabetologica</i> , 2008 , 45, 195-6 | 3.9 | 1 |
| 13 | Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 427-8 | 2.4 | 2 |
| 12 | Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3633-9 | | 17 |
| 11 | IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. <i>Pharmacogenomics</i> , 2006 , 7, 683-95 | 2.6 | 62 |
| 10 | Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraprolin expression. <i>Journal of Rheumatology</i> , 2005 , 32, 998-1005 | 4.1 | 9 |
| 9 | B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. <i>Thrombosis and Haemostasis</i> , 2004 , 92, 1150-1153 | 7 | 19 |
| 8 | Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 613-5 | 2.4 | 8 |
| 7 | Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers. <i>Autoimmunity Reviews</i> , 2004 , 3, 261-6 | 13.6 | 27 |
| 6 | Relationship between the tumor necrosis factor receptor II (TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in rheumatoid arthritis. <i>Human Immunology</i> , 2004 , 65, 1420-3 | 2.3 | 14 |
| 5 | B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. <i>Thrombosis and Haemostasis</i> , 2004 , 92, 1150-3 | 7 | 4 |
| 4 | Platelet GPIIb/IIIa (P1A 1/2) polymorphism in SLE: clinical and laboratory association. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 781-2 | 2.4 | 4 |
| 3 | Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. <i>Blood Cells, Molecules, and Diseases</i> , 2001 , 27, 757-66 | 2.1 | 31 |
| 2 | Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy. <i>Pharmacological Research</i> , 1999 , 40, 483-6 | 10.2 | 5 |

1 Sarilumab use in severe SARS-CoV-2 pneumonia

5